{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:59:58Z","timestamp":1785427198184,"version":"3.56.0"},"reference-count":54,"publisher":"Akademiai Kiado Zrt.","issue":"3","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,1,19]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    El\u0151rehaladott Parkinson-k\u00f3rban az oralisan, illetve\n                    transdermalisan adagolt dopaminerg szerek m\u00e1r nem el\u00e9g hat\u00e9konyak, \u00e9s jelent\u0151s\n                    mell\u00e9khat\u00e1ssal b\u00edrnak, ez\u00e9rt sz\u00fcks\u00e9g lehet a folyamatos dopaminerg stimul\u00e1ci\u00f3\n                    elv\u00e9n alapul\u00f3 eszk\u00f6z\u00f6s ter\u00e1pi\u00e1k valamelyik\u00e9re.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    C\u00e9lunk volt \u00f6sszehasonl\u00edtani a levodopa-entakapon-karbidopa intestinalis g\u00e9llel\n                    kezelt, el\u0151rehaladott Parkinson-k\u00f3ros betegeink klinikai param\u00e9tereit a kezel\u00e9s\n                    megkezd\u00e9se el\u0151tt \u00e9s k\u00f6zvetlen\u00fcl a klinik\u00e1r\u00f3l val\u00f3 elbocs\u00e1t\u00e1skor.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    Retrospekt\u00edven elemezt\u00fck azokat az azonos\n                    szempontok alapj\u00e1n nyert adatokat, amelyek a kezel\u00e9sben r\u00e9szes\u00fcl\u0151 betegekre\n                    vonatkoztak, figyelembe v\u00e9ve a betegek \u00e1ltal\u00e1nos \u00e9s neurol\u00f3giai \u00e1llapot\u00e1t \u00e9s\n                    annak ingadoz\u00e1sait, az el\u0151zetes kezel\u00e9si s\u00e9m\u00e1kat, a gy\u00f3gyszerel\u00e9s mell\u00e9khat\u00e1sait\n                    \u00e9s a Parkinson-k\u00f3r sz\u00f6v\u0151dm\u00e9nyeit.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    K\u00e9t \u00e9v alatt 29\n                    betegn\u00e9l vezett\u00fck be a levodopa-entakapon-karbidopa intestinalis g\u00e9l kezel\u00e9st,\n                    ezt megel\u0151z\u0151en \u00e1tlagosan 4,7 \u00b1 0,8 \u00f3r\u00e1s\n                    <jats:italic>off<\/jats:italic>\n                    \u00e1llapot mellett 20\n                    betegn\u00e9l tapasztaltunk \u00e1tlagosan 2,8 \u00b1 1,2 \u00f3r\u00e1s k\u00f6zepesen s\u00falyos\n                    cs\u00facsd\u00f3zis-dyskinesist, illetve 6 esetben 2,1 \u00b1 1,0 \u00f3r\u00e1s s\u00falyos dyskinesist. A\n                    kezel\u00e9s elind\u00edt\u00e1sa ut\u00e1n az\n                    <jats:italic>off<\/jats:italic>\n                    \u00e1llapot id\u0151tartama\n                    szignifik\u00e1nsan cs\u00f6kkent. Hasonl\u00f3 volt a tendencia az enyhe vagy k\u00f6z\u00e9ps\u00falyos\n                    dyskinesisek eset\u00e9ben, ugyanakkor a s\u00falyos dyskinesisek teljes m\u00e9rt\u00e9kben\n                    megsz\u0171ntek. Szint\u00e9n nem tapasztaltuk hazabocs\u00e1t\u00e1skor a 7 betegn\u00e9l kor\u00e1bban\n                    jelentkez\u0151 hirtelen\n                    <jats:italic>off<\/jats:italic>\n                    \u00e1llapotokat. A 24 esetben jelentkez\u0151\n                    kora hajnali akineticus \u00e1llapotot a v\u00e9gs\u0151 felm\u00e9r\u00e9skor m\u00e1r csak 8 beteg jelezte.\n                    <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic>\n                    Hab\u00e1r a Parkinson-k\u00f3ros betegek megk\u00e9sve, a\n                    megengedettn\u00e9l s\u00falyosabb motoros komplik\u00e1ci\u00f3kkal kezdt\u00e9k el a kezel\u00e9st, a\n                    levodopa-entakapon-karbidopa intestinalis g\u00e9l bevezet\u00e9se hat\u00e9konynak bizonyult.\n                    A vizsg\u00e1lt peri\u00f3dus alatt \u00e9szlelt enyhe, m\u00fal\u00f3 mell\u00e9khat\u00e1sok az irodalomban\n                    jelzett szinten voltak. Egyetlen entakaponnaiv betegben sem jelentkeztek\n                    gastrointestinalis mell\u00e9khat\u00e1sok.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A\n                    levodopa-entakapon-karbidopa intestinalis g\u00e9l motoros komplik\u00e1ci\u00f3kat jav\u00edt\u00f3\n                    hat\u00e1sa a levodopa-karbidopa intestinalis g\u00e9lhez hasonl\u00f3 m\u00e9rt\u00e9k\u0171, a napi kisebb\n                    levodopaadag \u00e9s a kisebb m\u00e9ret\u0171 adagol\u00f3szerkezet el\u0151nyeivel. Tov\u00e1bbi vizsg\u00e1latok\n                    \u00e9s t\u00f6bb klinikai tapasztalat \u00f6sszegz\u00e9se sz\u00fcks\u00e9ges annak eld\u00f6nt\u00e9s\u00e9re, hogy a\n                    levodop\u00e1t tartalmaz\u00f3 k\u00e9t enteralis g\u00e9lt\u00edpus k\u00f6z\u00fcl melyik el\u0151ny\u00f6sebb az egy\u00e9nre\n                    szabott kezel\u00e9si strat\u00e9gia keret\u00e9ben. A hossz\u00fa t\u00e1v\u00fa biztons\u00e1gos alkalmaz\u00e1s \u00e9s a\n                    motoros komplik\u00e1ci\u00f3k hat\u00e9kony enyh\u00edt\u00e9se egyar\u00e1nt fontos szempont ebben a\n                    d\u00f6nt\u00e9sben, a beteg \u00e9letmin\u0151s\u00e9g\u00e9nek jav\u00edt\u00e1sa \u00e9rdek\u00e9ben. Orv Hetil. 2025; 166(3):\n                    90\u201397.\n                  <\/jats:p>","DOI":"10.1556\/650.2025.33207","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T10:07:29Z","timestamp":1737540449000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["El\u0151rehaladott Parkinson-k\u00f3ros betegek kezel\u00e9se levodopa-entakapon-karbidopa intestinalis g\u00e9llel: az els\u0151 k\u00e9t \u00e9v tapasztalata"],"prefix":"10.1556","volume":"166","author":[{"given":"Szabolcs","family":"Szatm\u00e1ri","sequence":"first","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"2. Sz. Ideggy\u00f3gy\u00e1szati Klinika, Maros Megyei Klinikai S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef Attila","family":"Sz\u00e1sz","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"2. Sz. Ideggy\u00f3gy\u00e1szati Klinika, Maros Megyei Klinikai S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorelia","family":"Constantin","sequence":"additional","affiliation":[{"name":"2. Sz. Ideggy\u00f3gy\u00e1szati Klinika, Maros Megyei Klinikai S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Mih\u00e1ly","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem, \u00c9lettani Tansz\u00e9k Marosv\u00e1s\u00e1rhely Romania"},{"name":"Cs\u00edkszeredai Megyei S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z, Ideggy\u00f3gy\u00e1szati Oszt\u00e1ly Cs\u00edkszereda Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"2. Sz. Seb\u00e9szeti Klinika, Maros Megyei S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ciorba","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Gasztroenterol\u00f3giai Klinika, Maros Megyei S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imola","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Gasztroenterol\u00f3giai Klinika, Maros Megyei S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Kelemen","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"2. Sz. Ideggy\u00f3gy\u00e1szati Klinika, Maros Megyei Klinikai S\u00fcrg\u0151ss\u00e9gi K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"},{"name":"Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem, \u00c9lettani Tansz\u00e9k Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Sz\u00e1sz","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Szilvester","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Bar\u00f3ti","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem, Radiol\u00f3giai Tansz\u00e9k Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Frigy","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Kardiol\u00f3giai Klinika, Maros Megyei K\u00f3rh\u00e1z Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Orb\u00e1n-Kis","sequence":"additional","affiliation":[{"name":"Universitatea de Medicin\u0103, Farmacie, \u0218tiin\u021be \u0219i Tehnologie \u201eGeorge Emil Palade\u201d din T\u00e2rgu Mures (Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem) Marosv\u00e1s\u00e1rhely, Gral Ion Dumitrache u. 20\/A, 540081 Romania"},{"name":"Marosv\u00e1s\u00e1rhelyi George Emil Palade Orvosi, Gy\u00f3gyszer\u00e9szeti, Tudom\u00e1ny \u00e9s Technol\u00f3giai Egyetem, \u00c9lettani Tansz\u00e9k Marosv\u00e1s\u00e1rhely Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Pirto\u0161ek Z, Bajenaru O, Kov\u00e1cs N, et al. Update on the management of\n                    Parkinson\u2019s disease for general neurologists. Parkinsons Dis. 2020; 2020:\n                    9131474.","DOI":"10.1155\/2020\/9131474"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Barta A, Delb\u00f3 K, Varga \u00c9K, et al. Translation from Latin to\n                    Hungarian of the thesis of Ferenc P\u00e1pai P\u00e1riz at the 350th anniversary of his\n                    defense and medical inauguration at the University of Basel. [P\u00e1pai P\u00e1riz Ferenc\n                    baseli egyetemi diplomamunk\u00e1j\u00e1nak latinr\u00f3l magyarra ford\u00edt\u00e1sa v\u00e9d\u00e9s\u00e9nek \u00e9s\n                    orvoss\u00e1 avat\u00e1s\u00e1nak 350. \u00e9vfordul\u00f3j\u00e1n.] Orv Hetil. 2024; 165: 1808\u20131821.\n                    [Hungarian]","DOI":"10.1556\/650.2024.HO2818"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Bereczki D. The description of all four cardinal signs of\n                    Parkinson\u2019s disease in a Hungarian medical text published in 1690. Parkinsonism\n                    Relat Disord. 2010; 16: 290\u2013293.","DOI":"10.1016\/j.parkreldis.2009.11.006"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of\n                    Parkinson disease: a guide for neuroscientists. J Neurochem. 2016; 139(Suppl 1):\n                    325\u2013337.","DOI":"10.1111\/jnc.13750"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias\n                    and motor fluctuations as estimated from the cumulative literature. Mov Disord.\n                    2001; 16: 448\u2013458.","DOI":"10.1002\/mds.1090"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Szatm\u00e1ri S, Constantin V, et al. Characteristics of\n                    levodopa treatment in advanced Parkinson\u2019s disease in the experiences of the\n                    neurology clinics of T\u00e2rgu Mures, Romania. [Az or\u00e1lis levodopakezel\u00e9s\n                    jellegzetess\u00e9gei el\u0151rehaladott Parkinson-k\u00f3rban a marosv\u00e1s\u00e1rhelyi neurol\u00f3giai\n                    klinik\u00e1k tapasztalat\u00e1ban.] Orv Hetil. 2019; 160: 662\u2013669.\n                    [Hungarian]","DOI":"10.1556\/650.2019.31354"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Antonini A, D\u2019Onofrio V, Guerra A. Current and novel infusion\n                    therapies for patients with Parkinson\u2019s disease. J Neural Transm. 2023; 130:\n                    1349\u20131358.","DOI":"10.1007\/s00702-023-02693-8"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Constantin V, Sz\u00e1sz JA, Dulamea AO, et al. Impact of infusion\n                    therapies on quality of life in advanced Parkinson\u2019s disease. Neuropsychiatr Dis\n                    Treat. 2023; 19: 1959\u20131972.","DOI":"10.2147\/NDT.S422717"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa\n                    intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry.\n                    Parkinsonism Relat Disord. 2017; 45: 13\u201320.","DOI":"10.1016\/j.parkreldis.2017.09.018"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2:\n                    Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s\n                    disease. Mov Disord. 2019; 34: 353\u2013365.","DOI":"10.1002\/mds.27626"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Juh\u00e1sz A, Aschermann Z, \u00c1cs P, et al. Levodopa\/carbidopa intestinal\n                    gel can improve both motor and non-motor experiences of daily living in\n                    Parkinson\u2019s disease: an open-label study. Parkinsonism Relat Disord. 2017; 37:\n                    79\u201386.","DOI":"10.1016\/j.parkreldis.2017.02.001"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"B\u0103jenaru O, Ene A, Popescu BO, et al. The effect of\n                    levodopa-carbidopa intestinal gel infusion long-term therapy on motor\n                    complications in advanced Parkinson\u2019s disease: a multicenter Romanian\n                    experience. J Neural Transm. 2016; 123: 407\u2013414.","DOI":"10.1007\/s00702-015-1496-z"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Szatm\u00e1ri S, Constantin V, et al. Decision-making and\n                    duration to accept device-aided therapy in advanced Parkinson\u2019s disease.\n                    Retrospective data from an Eastern European center with high patient turnover.\n                    [D\u00f6nt\u00e9si szempontok \u00e9s az eszk\u00f6z\u00f6s ter\u00e1pia elfogad\u00e1s\u00e1hoz sz\u00fcks\u00e9ges id\u0151\n                    el\u0151rehaladott Parkinson-k\u00f3rban. Egy nagy betegforgalm\u00fa k\u00f6z\u00e9p-eur\u00f3pai k\u00f6zpont\n                    retospekt\u00edv adatai] Orv Hetil. 2021; 162: 839\u2013847. [Hungarian]","DOI":"10.1556\/650.2021.32083"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Szasz JA, Jianu DC, Simu MA, et al. Characterizing advanced\n                    Parkinson\u2019s disease: Romanian subanalysis from the OBSERVE-PD study. Parkinsons\n                    Dis. 2021; 2021: 6635618.","DOI":"10.1155\/2021\/6635618"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Dulamea AO, Constantin VA, et al.\n                    Levodopa-carbidopa-entacapone intestinal gel in advanced Parkinson disease: a\n                    multicenter real-life experience. Am J Ther. 2024; 31:\n                    e209\u2013e218.","DOI":"10.1097\/MJT.0000000000001707"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Nyholm D, Jost WH. An updated calculator for determining\n                    levodopa-equivalent dose. Neurol Res Pract. 2021; 3: 58.","DOI":"10.1186\/s42466-021-00157-6"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Nyholm D, Jost WH. Levodopa-entacapone-carbidopa intestinal gel\n                    infusion in advanced Parkinson\u2019s disease: real-world experience and practical\n                    guidance. Ther Adv Neurol Disord. 2022; 15: 17562864221108018.","DOI":"10.1177\/17562864221108018"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson\u2019s\n                    disease. Mov Disord. 2011; 26: 1049\u20131055.","DOI":"10.1002\/mds.23732"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Nagy EE, Frigy A, Sz\u00e1sz JA, et al. Neuroinflammation and\n                    microglia\/macrophage phenotype modulate the molecular background of post-stroke\n                    depression: a literature review. Exp Ther Med. 2020; 20:\n                    2510\u20132523.","DOI":"10.3892\/etm.2020.8933"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Fabbri M, Ferreira JJ, Lees A, et al. Opicapone for the treatment of\n                    Parkinson\u2019s disease: a review of a new licensed medicine. Mov Disord. 2018; 33:\n                    1528\u20131539.","DOI":"10.1002\/mds.27475"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of\n                    safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations.\n                    Mov Disord. 2014; 29: 229\u2013237.","DOI":"10.1002\/mds.25751"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Borgohain R, Sz\u00e1sz J, Stanzione P, et al. Two-year, randomized,\n                    controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s\n                    disease. Mov Disord. 2014; 29: 1273\u20131280.","DOI":"10.1002\/mds.25961"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Constantin VA, Orb\u00e1n-Kis K, et al. Levodopa-carbidopa\n                    intestinal gel in advanced Parkinson\u2019s disease: observations and dilemmas after\n                    10 years of real-life experience. Pharmaceutics 2022; 14: 1115.","DOI":"10.3390\/pharmaceutics14061115"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Fasano A, Gurevich T, Jech R, et al. Concomitant medication usage\n                    with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov\n                    Disord. 2021; 36: 1853\u20131862.","DOI":"10.1002\/mds.28596"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs N, Sz\u00e1sz J, Vela-Desojo L, et al. Motor and nonmotor symptoms\n                    in patients treated with 24-hour daily levodopa-carbidopa intestinal gel\n                    infusion: analysis of the COmedication Study assessing Mono- and cOmbination\n                    therapy with levodopa-carbidopa inteStinal gel (COSMOS). Parkinsonism Relat\n                    Disord. 2022; 105: 139\u2013144.","DOI":"10.1016\/j.parkreldis.2022.08.002"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Szatm\u00e1ri S, Constantin V, et al. The importance of\n                    evaluation of gastrointestinal symptoms in advanced Parkinson\u2019s disease. [A\n                    gastrointestinalis panaszok felm\u00e9r\u00e9s\u00e9nek jelent\u0151s\u00e9ge el\u0151rehaladott\n                    Parkinson-k\u00f3rban.] Orv Hetil. 2020; 161: 1681\u20131687. [Hungarian]","DOI":"10.1556\/650.2020.31782"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Freire-Alvarez E, Kur\u010da E, Lopez Manzanares L, et al.\n                    Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a\n                    randomized trial. Mov Disord. 2021; 36: 2615\u20132623.","DOI":"10.1002\/mds.28703"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"M\u00fcller T, Laar T van, Cornblath DR, et al. Peripheral neuropathy in\n                    Parkinson\u2019s disease: levodopa exposure and implications for duodenal delivery.\n                    Parkinsonism Relat Disord. 2013; 19: 501\u2013507.","DOI":"10.1016\/j.parkreldis.2013.02.006"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Liu XD, Bao Y, Liu GJ. Comparison between levodopa-carbidopa\n                    intestinal gel infusion and subthalamic nucleus deep-brain stimulation for\n                    advanced Parkinson\u2019s disease: a systematic review and meta-analysis. Front\n                    Neurol. 2019; 10: 934.","DOI":"10.3389\/fneur.2019.00934"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a\n                    peripherally acting catechol-O-methyltransferase inhibitor, on the motor\n                    response to acute treatment with levodopa in patients with Parkinson\u2019s disease.\n                    J Neurol Neurosurg Psychiatry 1994; 57: 186\u2013189.","DOI":"10.1136\/jnnp.57.2.186"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Kuoppam\u00e4ki M, Leinonen M, Poewe W. Efficacy and safety of entacapone\n                    in levodopa\/carbidopa versus levodopa\/benserazide treated Parkinson\u2019s disease\n                    patients with wearing-off. J Neural Transm. 2015; 122:\n                    1709\u20131714.","DOI":"10.1007\/s00702-015-1449-6"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Habet S. Clinical pharmacology of entacapone (Comtan) from the FDA\n                    reviewer. Int J Neuropsychopharmacol. 2022; 25: 567\u2013575.","DOI":"10.1093\/ijnp\/pyac021"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Nyholm D, Johansson A, Lennern\u00e4s H, et al. Levodopa infusion\n                    combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J\n                    Neurol. 2012; 19: 820\u2013826.","DOI":"10.1111\/j.1468-1331.2011.03614.x"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa\n                    intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord.\n                    2017; 32: 283\u2013286.","DOI":"10.1002\/mds.26855"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"\u00d6thman M, Widman E, Nygren I, et al. Initial experience of the\n                    levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med.\n                    2021; 11: 254.","DOI":"10.3390\/jpm11040254"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Viljaharju V, Mertsalmi T, Pauls KA, et al.\n                    Levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson\u2019s\n                    disease: a single-center study of 30 patients. Mov Disord Clin Pract. 2024; 11:\n                    159\u2013165.","DOI":"10.1002\/mdc3.13926"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Szatm\u00e1ri S, Sz\u00e1sz JA, Orb\u00e1n-Kis K, et al.\n                    Levodopa-entacapone-carbidopa intestinal gel in the treatment of advanced\n                    Parkinson\u2019s disease: a single center real-world experience. Pharmaceutic 2024;\n                    16: 453.","DOI":"10.3390\/pharmaceutics16040453"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of\n                    levodopa gel infusion in Parkinson\u2019s disease: effects of entacapone infusion and\n                    genetic polymorphism. Sci Rep. 2020; 10: 18057.","DOI":"10.1038\/s41598-020-75052-2"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Gy\u00f6rfi B, Bal\u00f3 B, Botz K, et al. Triple combination of levodopa,\n                    carbidopa and entacapone by intrajejunal pump in advanced Parkinson\u2019s disease.\n                    [Levodopa-entakapon-karbidopa intestinalis g\u00e9linf\u00fazi\u00f3 el\u0151rehaladott\n                    Parkinson-k\u00f3rban\u202f: \u00faj kezel\u00e9si lehet\u0151s\u00e9g intrajejunalis levodopa adagol\u00e1s\u00e1ra.]\n                    Ideggy\u00f3gy Szle. 2022; 75: 365\u2013368 [Hungarian]","DOI":"10.18071\/isz.75.0365"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Constantin VA, Orb\u00e1n-Kis K, et al. Profile of patients\n                    with advanced Parkinson\u2019s disease suitable for device-aided therapies:\n                    restrospective data of a large cohort of Romanian patients. Neuropsychiatr Dis\n                    Treat. 2019; 15: 3187\u20133195.","DOI":"10.2147\/NDT.S230052"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Constantin VA, Sz\u00e1sz JA, Orb\u00e1n-Kis K, et al. Levodopa-carbidopa\n                    intestinal gel infusion therapy discontinuation: a ten-year retrospective\n                    analysis of 204 treated patients. Neuropsychiatr Dis Treat. 2020; 16:\n                    1835\u20131844.","DOI":"10.2147\/NDT.S256988"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Constantin VA, Orb\u00e1n-Kis K, et al. Management challenges\n                    of severe, complex dyskinesia. Data from a large cohort of patients treated with\n                    levodopa-carbidopa intestinal gel for advanced Parkinson\u2019s disease. Brain Sci.\n                    2021; 11: 826.","DOI":"10.3390\/brainsci11070826"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician\n                    perspectives on non-oral medication approaches for the management of clinically\n                    relevant unresolved issues in Parkinson\u2019s disease: consensus from an\n                    international survey and discussion program. Parkinsonism Relat Disord. 2015;\n                    21: 1133\u20131144.","DOI":"10.1016\/j.parkreldis.2015.07.020"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, et al. Consensus on the\n                    definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study\n                    (CEPA study). Parkinsons Dis. 2017; 2017: 4047392.","DOI":"10.1155\/2017\/4047392"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus\n                    among movement disorder specialists on clinical indicators for identification\n                    and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel\n                    approach. Curr Med Res Opin. 2018; 34: 2063\u20132073.","DOI":"10.1080\/03007995.2018.1502165"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Moes HR, Henriksen T, S\u0142awek J, et al. Tools and criteria to select\n                    patients with advanced Parkinson\u2019s disease for device-aided therapies: a\n                    narrative review. J Neural Transm. 2023; 130: 1359\u20131377.","DOI":"10.1007\/s00702-023-02656-z"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Wolfgang HJ. A novel treatment option for intrajejunal levodopa\n                    administration. Expert Rev Neurother. 2023; 23: 9\u201313.","DOI":"10.1080\/14737175.2023.2176222"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Amjad F, Bhatti D, Davis TL, et al. Current practices for outpatient\n                    initiation of levodopa-carbidopa intestinal gel for management of advanced\n                    Parkinson\u2019s disease in the United States. Adv Ther. 2019; 36:\n                    2233\u20132246.","DOI":"10.1007\/s12325-019-01014-4"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Willows T, Dizdar N, Nyholm D, et al. Initiation of\n                    levodopa-carbidopa intestinal gel infusion using telemedicine (video\n                    communication system) facilitates efficient and well-accepted home titration in\n                    patients with advanced Parkinson\u2019s disease. J Parkinsons Dis. 2017; 7:\n                    719\u2013728.","DOI":"10.3233\/JPD-161048"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Simu MA, Jianu DC, Dulamea AO, et al. Advanced Parkinson\u2019s disease\n                    treatment simplification and long-term outcomes with levodopa carbidopa\n                    intestinal gel: COSMOS Romanian subanalysis. Brain Sci. 2021; 11:\n                    1566.","DOI":"10.3390\/brainsci11121566"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Orb\u00e1n-Kis K, Constantin VA, et al. Therapeutic strategies\n                    in the early stages of Parkinson\u2019s disease: a cross-sectional evaluation of 15\n                    years\u2019 experience with a large cohort of Romanian patients. Neuropsychiatr Dis\n                    Treat. 2019; 15: 831\u2013838.","DOI":"10.2147\/NDT.S197630"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Constantin V, Mih\u00e1ly I, et al. Dopamine agonists in\n                    Parkinson\u2019s disease therapy \u2013 15 years of experience of the neurological clinics\n                    from T\u00eergu Mure\u0219. A cross-sectional study. [A dopaminagonist\u00e1k jelent\u0151s\u00e9ge a\n                    Parkinson-k\u00f3r kezel\u00e9s\u00e9ben a marosv\u00e1s\u00e1rhelyi ideggy\u00f3gy\u00e1szati klinik\u00e1k 15 \u00e9ves\n                    gyakorlat\u00e1ban \u2013 keresztmetszeti vizsg\u00e1lat.] Ideggy\u00f3gy Szle. 2019; 72: 187\u2013193.\n                    [Hungarian]","DOI":"10.18071\/isz.72.0187"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Constantin V, Fazakas PA, et al. The role of selective\n                    monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson\u2019s\n                    disease in the neurology clinics of T\u00eergu Mure\u0219 County Emergency Clinical\n                    Hospital. [A szelekt\u00edv monoaminoxid\u00e1z-B-g\u00e1tl\u00f3k helye a Parkinson-k\u00f3r kezel\u00e9si\n                    strat\u00e9gi\u00e1j\u00e1ban a marosv\u00e1s\u00e1rhelyi ideggy\u00f3gy\u00e1szati klinik\u00e1k gyakorlat\u00e1ban.] Orv\n                    Hetil. 2017; 158: 2023\u20132028. [Hungarian]","DOI":"10.1556\/650.2017.30914"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Sz\u00e1sz JA, Szatm\u00e1ri Sz, Constantin V, et al. Ten-year trends of the\n                    characteristics in patients with advanced Parkinson\u2019s disease at the time of\n                    intestinal gel therapy introduction. [Az intestinalis g\u00e9l bevezet\u00e9sekor\n                    r\u00f6gz\u00edtett jellemz\u0151k t\u00edz\u00e9ves v\u00e1ltoz\u00e1sai el\u0151rehaladott Parkinson-k\u00f3ros\n                    betegekben.] Orv Hetil. 2022; 163: 1189\u20131195. [Hungarian]","DOI":"10.1556\/650.2022.32534"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/3\/article-p90.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/3\/article-p90.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/3\/article-p90.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:02:34Z","timestamp":1785423754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/3\/article-p90.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":54,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33207","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]}}}